CADL
Candel Therapeutics, Inc.
There isn't enough reported data to score CADL yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CADL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
CADL's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CADL PE Valuation
CADL has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CADL Forward outlook
There aren't enough analyst estimates for CADL to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CADL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.49 | -$0.93 |
| Q2 2026 | -$1.42 | -$0.74 |
| Q1 2026 | -$0.99 | +$0.34 |
| Q4 2025 | -$0.72 | +$1.02 |
| Q3 2025 | -$0.56 | +$1.18 |
| Q2 2025 | -$0.68 | +$1.02 |
| Q1 2025 | -$1.33 | -$0.04 |
| Q4 2024 | -$1.74 | -$0.43 |
CADL lost $1.49 per share over the past year, and its loss has widened in each of the last four quarters.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CADL on earnings quality, reporting a profit while its opponent remains loss making.
CADL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $31K | 0% |
| Q3 2022 | $31K | 0% |
| Q2 2022 | $31K | 0% |
| Q1 2022 | $31K | 0% |
| Q4 2021 | $31K | 0% |
| Q3 2021 | $31K | 0% |
| Q2 2021 | $31K | 0% |
| Q1 2021 | $31K | 0% |
CADL has the stronger quarterly revenue trend. Revenue is flat for CADL versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -26132% | -1165 points |
| Q3 2022 | -28648% | -2748 points |
| Q2 2022 | -28235% | -11136 points |
| Q1 2022 | -28987% | -13965 points |
| Q4 2021 | -24968% | -5210 points |
| Q3 2021 | -25900% | -17032 points |
| Q2 2021 | -17100% | -8652 points |
| Q1 2021 | -15023% | -7545 points |
CADL's operating margin was −26132% last quarter, down 1165 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CADL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.3M | -$12.9M |
| Q2 2026 | -$17.3M | -$8.3M |
| Q1 2026 | -$18.7M | -$10.1M |
| Q4 2025 | -$11M | -$5.2M |
| Q3 2025 | -$10.4M | -$3.8M |
| Q2 2025 | -$8.9M | -$2.7M |
| Q1 2025 | -$8.6M | -$174K |
| Q4 2024 | -$5.8M | +$1.7M |
CADL has burned cash in almost every quarter: −$70M over the past year, against −$34M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CADL on cash generation, producing positive trailing cash flow while its opponent burns cash.
CADL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.4% | +3.3M shares |
| 1 year | +50% | +25.9M shares |
| 3 years | +168% | +48.5M shares |
| 5 years | +566% | +65.8M shares |
CADL has 77M diluted shares, up 50% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CADL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CADL Net Leverage
CADL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CADL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 12.5 | Oversold |
CADL's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CADL PE vs Healthcare Sector
CADL has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CADL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.10 | 7.8% below |
| 20 week MA | $10.2 | 18% below |
| 50 week MA | $7.93 | 5.8% above |
| 100 week MA | $7.10 | 18% above |
| 200 week MA | $5.18 | 62% above |
CADL has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 62% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CADL on trend strength, trading above more of its moving averages.
CADL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $7.59 | $8.40 | +11% |
| 2022 | $8.40 | $1.52 | -82% |
| 2023 | $1.52 | $1.47 | -3.3% |
| 2024 | $1.47 | $8.87 | +503% |
| 2025 | $8.87 | $6.01 | -32% |
| 2026 YTD | $6.01 | $8.39 | +40% |
CADL has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.